Market Place
Sourcing Support
US FDA staff flags risk of low blood sugar for Novo Nordisk`s weekly insulin
23 May 2024 //
REUTERS
Novo Nordisk to discontinue Levemir insulin in U.S. market
09 Nov 2023 //
REUTERS
Novo`s insulin degludec:Liraglutide Receives Approval in the U.S.
01 Jul 2022 //
FDA
Once-weekly insulin icodec shows superior reduction in HbA1c vs insulin degludec
28 Apr 2022 //
GLOBENEWSWIRE
Novo Nordisk Issues Voluntary Nationwide Recall of Levemir®
11 May 2021 //
FDA
Tresiba lowers risk of hypos in type II diabetes
20 Sep 2019 //
PHARMATIMES
Novo`s Tresiba misses main mark in head-to-head Toujeo tilt
19 Sep 2019 //
FIERCE PHARMA
Novo faces shareholder suit over insulin sales disclosures
16 Aug 2019 //
BIOPHARMADIVE
Sanofi talks up personalized diabetes care in patient-centric awareness push
10 Jun 2019 //
FIERCE PHARMA
Sanofi`s Toujeo tops Novo Nordisk`s Tresiba in tough-to-treat diabetes subgroup
10 Jun 2019 //
FIERCE PHARMA
Study shows reduced hypoglycaemia after switch to Tresiba
11 Mar 2019 //
PHARMA TIMES
Novo’s oral semaglutide could disrupt diabetes coverage: analyst
05 Mar 2019 //
FIERCE PHARMA
Novo Nordisk preps for speedy oral GLP-1 drug filing
01 Feb 2019 //
PM LIVE
Novo Nordisk sees revenues drop in Q2
09 Aug 2018 //
PHARMA TIMES
Drugmaker Novo Nordisk sales disappoint, sees lower 2019 U.S. prices
08 Aug 2018 //
REUTERS
Novo Nordisk’s Ozempic is quick out of the blocks, chasing Lilly’s Trulicity
08 Aug 2018 //
PM LIVE
Celgene, Roche and Novo increased prices on some top sellers
13 Jul 2018 //
FIERCE PHARMA
Sanofi presents positive results of long-acting insulin Toujeo
05 Jul 2018 //
BIOSPECTRUM
Novo`s Tresiba snags FDA nod highlighting hypo safety
26 Mar 2018 //
FIERCE PHARMA
Sanofi bets on India with portfolio of drugs for diabetes, rare diseases
13 Feb 2018 //
ECONOMIC TIMES
Insulia receives FDA clearance and CE mark to integrate Basaglar and Tresiba
16 Nov 2017 //
PR NEWSWIRE
CHMP endorses Tresiba label update in the EU
02 Oct 2017 //
PHARMA TIMES
Cardiovascular outcomes dominate EASD
14 Sep 2017 //
PHARMA TIMES
When `New and Improved` Fails: Insulin Maker -2-
15 Aug 2017 //
WALL STREET JOURNAL
Novo moves to add Lantus-matching CV data to Tresiba`s European label
16 Jun 2017 //
FIERCE PHARMA
Novo`s Tresiba matches Sanofi rival Lantus in CV safety
12 Jun 2017 //
FIERCE PHARMA
Tresiba® demonstrated no increased risk of major cardiovascular event
12 Jun 2017 //
PR NEWSWIRE
Robert A. Ingram Named Chairman of BioCryst Pharmaceuticals, Inc.
30 May 2017 //
GLOBENEWSWIRE
Novo CEO cites `volatile` environment, US politics in cut to 2017 growth
02 Feb 2017 //
FIERCE PHARMA
Sanofi beats Novo to launch with diabetes combo Soliqua
06 Jan 2017 //
FIERCE PHARMA
Sanofi Sues Novo Over `Misleading` Tresiba Marketing Materials
28 Dec 2016 //
FIERCE PHARMA
Novo Receives FDA Approval of Tresiba with Diabetes
20 Dec 2016 //
PR NEWSWIRE
Novo Nordisk Reports Tresiba Insulin Achieves Target in Study
30 Nov 2016 //
REUTERS
Oramed Vs. Novo Nordisk In Race For Oral GLP-1
29 Nov 2016 //
NASDAQ
Novo, Sanofi go head to head as FDA clears new diabetes drugs
24 Nov 2016 //
JAPAN TODAY
Novo Nordisk receives FDA approval for Xultophy® 100 / 3.6 in the United States
21 Nov 2016 //
GLOBENEWSWIRE
Novo Nordisk`s Tresiba Backed for use on NHS Wales
28 Oct 2016 //
PHARMATIMES
That head start for Novo`s combo med Xultophy? The FDA delayed it instead
07 Sep 2016 //
FIERCE PHARMA
Novo Nordisk`s Tresiba gaining ground in basal insulin market
06 Aug 2016 //
PMLIVE
Novo`s Tresiba hits the airwaves with new TV campaign
22 Jun 2016 //
FIERCE PHARMA
Novo’s Tresiba beats Sanofi’s Lantus on reducing hypoglycaemi
16 Jun 2016 //
PHARMATIMES
IDegLira receives unanimous 16-0 vote in favor of approval from FDA Advisory Committee
25 May 2016 //
GLOBAL NEWS WIRE
New T2D Drugs Face Skeptical FDA Advisors
24 May 2016 //
MEDPAGE TODAY
